Ⓐ
PeptiBrief
Evidence Library
first_in_human_study · 2015

Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist

Brame AL|Maguire JJ|Yang P|Dyson A|Torella R|Cheriyan J|Singer M|Glen RC|Wilkinson IB|Davenport AP · Hypertension
moderateDOI · 10.1161/hypertensionaha.114.05099PMID · 25712721Verified
View source
Plain-English summary

The study confirmed that apelin-receptor agonism can produce measurable vasodilation in humans.

Population
Healthy volunteers
Intervention
Intravenous biased apelin-receptor agonist
Outcomes measured
Forearm blood flow|Blood pressure|Safety|Pharmacology
Key findings
Demonstrated human vascular target engagement.
Limitations
Early phase|Small sample|Short-term vascular endpoints|Synthetic agonist rather than native apelin-13
Risk of bias
Moderate for acute target engagement; insufficient for clinical outcomes.
Citation
Brame AL|Maguire JJ|Yang P|Dyson A|Torella R|Cheriyan J|Singer M|Glen RC|Wilkinson IB|Davenport AP (2015). Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. https://doi.org/10.1161/hypertensionaha.114.05099
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.